Skip to main content
USA News
 

MASON, Ohio --(BUSINESS WIRE)--Apr. 1, 2019-- AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in surgical treatments for atrial fibrillation (Afib) and left atrial appendage management, today announced that it will present at the Needham & Company’s 18 th Annual Healthcare Conference in New

 

MASON, Ohio --(BUSINESS WIRE)--Dec. 13, 2018-- AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in surgical treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that it will present at the 37 th Annual J.P.

 

2018 Worldwide revenue of $201 .6 million – an increase of 15.4% year over year 2018 U.S. revenue of $162 .1 million – an increase of 17.2% year over year 2018 International revenue of $39 .5 million – an increase of 8.7% year over year MASON, Ohio --(BUSINESS WIRE)--Feb. 28, 2019-- AtriCure, Inc.

 

Endorsement complements the company’s ongoing commitment to physician education MASON, Ohio --(BUSINESS WIRE)--Feb. 19, 2019-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatment for atrial fibrillation (Afib) and left atrial appendage management, today announced that The

 

MASON, Ohio --(BUSINESS WIRE)--Oct. 22, 2018-- AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in surgical treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that it will be participating in upcoming investor conferences.

 

MASON, Ohio --(BUSINESS WIRE)--Oct. 11, 2018-- AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that it will release its third quarter 2018 financial results on Thursday, November 1, 2018 .

 

MASON, Ohio --(BUSINESS WIRE)--Oct. 4, 2018-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced the pricing of its underwritten offering of 2.5 million shares of its common stock at a price to

 

MASON, Ohio --(BUSINESS WIRE)--Oct. 3, 2018-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced it has commenced an underwritten public offering of 2.5 million shares of its common stock

 

MASON, Ohio --(BUSINESS WIRE)--Nov. 8, 2018-- AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in surgical treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that it will present at the Piper Jaffray 30 th Annual Healthcare Conference in New

 

Worldwide revenue of $49 .9 million – an increase of 18.5% year over year U.S. revenue of $39 .8 million – an increase of 19.1% year over year International revenue of $10 .2 million – an increase of 16.2% year over year MASON, Ohio --(BUSINESS WIRE)--Nov. 1, 2018-- AtriCure, Inc.